29 March 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at Proactive Investors One2One Investor Forum
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that the Group's Chief Executive, Alastair Smith, will be presenting at the Proactive Investors One2One Investor Forum on the 5 April 2018 at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB.
The evening event, which begins at 6pm, provides an opportunity for investors to hear about the opportunity for the Group's Affimer® technology, its development plans and to discuss these with Alastair.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer |
Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang |
Tel: +44 (0) 207 220 0500 www.finncap.com Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk |
Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey PR (Financial Media and IR) Sarah Hollins |
Tel: +44 (0)7787 502 947 [email protected] Tel: +44 (0)7764 947137 [email protected] |
To register for Avacta news alerts by email go to www.avacta.com/investor-news-email-alerts
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
